Passage BIO
| General Information | |
| Business: |
We are a genetic medicines company focused on developing transformative therapies for rare, monogenic CNS disorders with limited or no approved treatment options. Our vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients suffering from these life-threatening disorders. |
| Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
| Employees: | 20 |
| Founded: | 2017 |
| Contact Information | |
| Address | Two Commerce Square, 2001 Market Street, 28th Floor, Philadelphia, PA, 19103, US |
| Phone Number | (267) 866-0311 |
| Web Address | http://www.passagebio.com |
| View Prospectus: | Passage BIO |
| Financial Information | |
| Market Cap | $792.0mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-45.6 mil (last 12 months) |
| IPO Profile | |
| Symbol | PASG |
| Exchange | NASDAQ |
| Shares (millions): | 12.0 |
| Price range | $18.00 - $18.00 |
| Est. $ Volume | $216.0 mil |
| Manager / Joint Managers | J.P. Morgan/ Goldman Sachs/ Cowen and Company |
| CO-Managers | Chardan |
| Expected To Trade: | 2/28/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |